The Study of Efficacy and Safety of Mexidol® in Stroke Therapy (MIR)

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

November 18, 2019

Primary Completion Date

August 18, 2023

Study Completion Date

August 18, 2023

Conditions
Ischemic Stroke
Interventions
DRUG

Mexidol

50 mg/ml IV solution, 250 mg tablets

DRUG

Placebo

Placebo IV solution, Placebo tablets

Trial Locations (19)

100109

The first clinic of the Tashkent Medical Academy, Tashkent

117997

Federal Center for Brain and Neurotechnology, Moscow

Russian National Research Medical University n.a. N. I. Pirogov, Moscow

150030

Yaroslavl Clinical Hospital № 2, Yaroslavl

188643

Vsevolozhsk Clinical Interdistrict Hospital, Vsevolozhsk

193312

Alexandrovskaya Hospital, Saint Petersburg

196247

St. Petersburg Clinical Hospital № 26, Saint Petersburg

197341

National Medical Research Center n.a. V. A. Almazov, Saint Petersburg

197706

City Hospital № 40 of Kurortny District, Saint Petersburg

344022

Rostov State Medical University, Rostov-on-Don

350086

Research Institute - Regional Clinical Hospital № 1, Krasnodar

394066

Voronezh Regional Clinical Hospital № 1, Voronezh

410064

Tatarstan Republican Clinical Hospital, Kazan'

420101

Interregional Clinical Diagnostic Center, Kazan'

420103

Kazan City Hospital № 7, Kazan'

432026

Central Clinical Medical and Sanitary Unit n.a. V. A. Egorov, Ulyanovsk

443095

Samara Regional Clinical Hospital n.a. V. D. Seredavin, Samara

650014

Kemerovo City Clinical Hospital № 11, Kemerovo

050006

Almaty City Hospital № 7, Almaty

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmasoft

INDUSTRY